The identification of ebselen (compound 1, Figure 22.1) as a plausible anti SARS-CoV-main protease inhibitor, within the article that can be considered the first drug repurposing approach ever reported in the context of COVID19,¹  lead to renewed interest around the use of selenorganic compounds as antivirals,^2,3  among other therapeutic applications.^4–8  From a historical perspective the first selenium-containing antiviral is selenazofurin (compound 2), developed in 1983 by Kirsi, able to inhibit the replication of a plethora of DNA and RNA viruses with a potency which was far higher than that displayed by its sulfur analog, thiazafurin (not shown), and of the marketed, broad spectrum drug ribavirin.⁹  Then, ebselen itself was found to be active as an anti-HIV compound due to its ability to block tat-mediated transcription¹⁰  and covalently bind the capsid protein.¹¹  The group of Mlochowski and Giurg contributed a lot by preparing several diselenides and benzisoselenazolones endowed with antiviral activities.^12–14  Some of us, in 2015, reported the identification of DiSelenoBisbenzAmides (DiSeBAs, compounds 3), diphenyldiselenides substituted in the ortho position with an amide functionality, capable of exerting a broad and selective antiviral activity.¹⁵  Their ability to inhibit viral replication is due to the inhibition of the key viral component NCp7, a zinc finger protein which is essential for the HIV to successfully duplicate.^16,17  Not only HIV-1 but also HIV-2 wild type and clinical isolates resistant to the marketed drugs are inhibited by DiSeBAs.¹⁵  Several reviews,³  books,¹⁸  and book chapters^7,19  have been devoted to this topic, and as a result the authors decided to limit the discussion to the most salient and timely examples of selenium-containing compounds endowed with antiviral activities detailing all the examples of compounds endowed with anti-SARS-CoV-2 properties.